帕比司他|T2383

價(jià)格	￥153	￥335	￥526
包裝	1mg	5mg	10mg

最小起訂量	1mg
發(fā)貨地	上海
更新日期	2024-12-02

QQ交談微信洽談

產(chǎn)品詳情

中文名稱:帕比司他	英文名稱:Panobinostat
CAS:404950-80-7	品牌: TargetMol
產(chǎn)地: 美國(guó)	保存條件: Powder: -20°C for 3 years \| In solvent: -80°C for 1 year \| Shipping with blue ice.
純度規(guī)格: 99.14%	產(chǎn)品類別: 抑制劑
貨號(hào): T2383

Product Introduction

Bioactivity

名稱	Panobinostat
描述	Panobinostat (NVP-LBH589) is a broad-spectrum HDAC inhibitor (IC50=5 nM) with oral activity and non-selectivity. Panobinostat has antitumor activity and induces apoptosis and autophagy.
細(xì)胞實(shí)驗(yàn)	Blasts from peripheral blood of 2 patients and from bone marrow of 4 patients were isolated with Ficoll-Hypaque, put in culture at a density of 500?000 cells/mL with RPMI-1640 medium containing 10% fetal bovine serum and 50 units/mL penicillin and streptomycin, and treated with different doses of LBH589 (0-100 μM) for up to 48 hours [1].
動(dòng)物實(shí)驗(yàn)	AE17 and TC-1 cancer cells (1 × 10^6 cells) were injected into the flanks of adult female C57Bl/6 mice and severe combined immunodeficiency (SCID) mice. M30 (10 × 10^6 cells), A549 (5 × 10^6 cells), H69 (2.5 × 10^6 cells), BK-T (6.5 × 10^6), H526 (10 × 10^6), and RG1 (10 × 10^6) cells were also injected, but in the presence of matrigel (BD Biosciences), into the flanks of SCID mice. There were 5 to 10 mice in each treatment group. The experiments with the A549 and H69 cell lines were repeated to ensure the statistical consistency of the results. Experiments were terminated when the tumors in the control mice had grown to a size that threatened the quality of life of the mice. When tumors reached 100 to 500 mm3, panobinostat was administered via i.p. injections (10–20 mg/kg) on a daily schedule (5-days-on, 2-days-off regimen) for the entire duration of the experiment. Control mice received i.p. injections with dextrose 5% in water ("vehicle treatment"). Every tumor was measured with a caliper at least twice weekly. For evaluation of the effects of combination therapy on SCLC-derived tumors, SCID mice with H69 tumors were administered panobinostat as described above. Three days after the initiation of panobinostat, and again 1 wk later, etoposide (40 mg/kg) was administered i.p [3].
體外活性	方法：37 種肺癌細(xì)胞系用 Panobinostat (0-800 nmol/L) 處理 48-72 h，使用 MTT 方法檢測(cè)細(xì)胞活力。結(jié)果：Panobinostat 對(duì)人和小鼠的肺癌細(xì)胞系表現(xiàn)出強(qiáng)大的抗增殖活性和細(xì)胞毒性。[1] 方法：人 ALL 細(xì)胞 MOLT-4 和 Reh 用 Panobinostat (10-100 nM) 處理 24-72 h，使用 Flow Cytometry 檢測(cè)細(xì)胞凋亡情況。結(jié)果：Panobinostat 以時(shí)間和劑量依賴的方式誘導(dǎo) MOLT-4 和 Reh 細(xì)胞的凋亡。[2]
體內(nèi)活性	方法：為檢測(cè)體內(nèi)抗腫瘤活性，將 Panobinostat (20 mg/kg) 腹腔注射給攜帶人 SCLC 腫瘤 H526、BKT、RG1 或 H69 的 SCID 小鼠，每周五次，持續(xù)兩周。結(jié)果：Panobinostat 顯著減緩源于 SCLC 細(xì)胞的腫瘤的體內(nèi)生長(zhǎng)并誘導(dǎo)緩解。[1] 方法：為研究對(duì)中風(fēng)后增強(qiáng)運(yùn)動(dòng)功能恢復(fù)的潛力，將 Panobinostat (3-10 mg/kg) 腹腔注射給中風(fēng)的 CD-1 小鼠，每?jī)商煲淮?，持續(xù)十天。結(jié)果：體育鍛煉與 Panobinostat 的結(jié)合都不會(huì)對(duì)中風(fēng)后小鼠的運(yùn)動(dòng)恢復(fù)產(chǎn)生實(shí)質(zhì)性影響。Panobinostat 治療加上有限的身體康復(fù)不太可能為患有運(yùn)動(dòng)功能障礙的中風(fēng)幸存者提供治療方式。[3]
存儲(chǔ)條件	Powder: -20°C for 3 years \| In solvent: -80°C for 1 year \| Shipping with blue ice.
溶解度	H2O : < 1 mg/mL (insoluble or slightly soluble) 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 6.4 mg/mL (18.32 mM), Please add co-solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. Ethanol : < 1 mg/mL (insoluble or slightly soluble) DMSO : 16.67 mg/mL (47.7 mM)
關(guān)鍵字	Human immunodeficiency virus \| Histone deacetylases \| NVP-LBH 589 \| HIV \| HDAC \| Autophagy \| inhibit \| Inhibitor \| Panobinostat \| LBH-589 \| Apoptosis \| NVP-LBH-589 \| LBH 589
相關(guān)產(chǎn)品	Guanidine hydrochloride \| Naringin \| Valproic Acid \| L-Glutamic acid \| Emtricitabine \| Hydroxychloroquine \| Lamivudine \| Dextran sulfate sodium salt (MW 4500-5500) \| Stavudine \| L-Ascorbic acid \| Paeonol \| Sodium 4-phenylbutyrate
相關(guān)庫(kù)	抗癌上市藥物庫(kù) \| 經(jīng)典已知活性庫(kù) \| 抗癌活性化合物庫(kù) \| 已知活性化合物庫(kù) \| EMA 上市藥物庫(kù) \| 抗病毒庫(kù) \| FDA 上市藥物庫(kù) \| 藥物功能重定位化合物庫(kù) \| 抗癌臨床化合物庫(kù) \| 抗癌藥物庫(kù)

關(guān)鍵字：帕比司他|||NVP-LBH589|||LBH589|TargetMol

公司簡(jiǎn)介

上海陶術(shù)生物科技有限公司為美國(guó)Target Molecule Corp. ( Target Mol ) 在上海建立的全資子公司。我們與美國(guó)波士頓、德國(guó)慕尼黑的同事一起，為北美、歐洲和亞洲從事藥物研發(fā)和生物學(xué)研究的科學(xué)家提供優(yōu)質(zhì)的產(chǎn)品和專業(yè)的服務(wù)。公司下設(shè)篩選事業(yè)部，化學(xué)事業(yè)部，生物事業(yè)部和新材料部。從虛擬篩選到實(shí)體化合物分子供應(yīng)；從商業(yè)化產(chǎn)品銷售到個(gè)性化定制合成；從對(duì)明確靶點(diǎn)的分子篩選到對(duì)明確分子的多靶點(diǎn)篩選，從高通量篩選到化學(xué)結(jié)構(gòu)優(yōu)化，我們都可以滿足您的科研用品及技術(shù)服務(wù)的需求。經(jīng)過(guò)在中國(guó)市場(chǎng)五年的精心耕耘，我們已成為篩選化合物領(lǐng)域優(yōu)秀的供應(yīng)商，為超過(guò)五百家學(xué)校和各類企業(yè)提供了品質(zhì)卓越的小分子化合物和藥物篩

成立日期	2013-04-18 （12年）	注冊(cè)資本	566.2651萬(wàn)人民幣
員工人數(shù)	100-500人	年?duì)I業(yè)額	￥ 1億以上
主營(yíng)行業(yè)	化學(xué)試劑,生物活性小分子	經(jīng)營(yíng)模式	貿(mào)易,試劑,定制,服務(wù)

TargetMol中國(guó)（陶術(shù)生物）

VIP 12年

公司成立：12年
注冊(cè)資本：566.2651萬(wàn)人民幣
企業(yè)類型：有限責(zé)任公司(自然人投資或控股)
主營(yíng)產(chǎn)品：小分子抑制劑，藥物篩選化合物庫(kù)，天然產(chǎn)物，活性分子化合物等
公司地址：上海市閘北區(qū)江場(chǎng)三路28號(hào)4樓

進(jìn)入店鋪

詢盤

店內(nèi)推薦

其他特殊品種庫(kù)

￥5000

雷帕霉素

￥286.00

雷帕霉素

￥396